News - Events & Presentations
RSS Feed

Esperion experts are often called upon to present at scientific and business conferences and events.
Here's where you can find us:

ETC-1002 Inhibits Inflammatory Response in Primary Human Monocyte-Derived Macrophages as well as in Adipose Tissue of Insulin Resistant Mice via AMPK-Dependent Mechanism
January 14, 2013

ETC-1002 Reduces Body Weight and Hepatic Triglyceride Content and Improves Insulin Sensitivity in a Mouse Model of Diet-Induced Obesity
January 14, 2013

ETC-1002 Lowers LDL-C and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects with Either Normal or Elevated Triglycerides
January 14, 2013

ETC-1002 Reduces Circulating and Hepatic Triglyceride Content and Improves Glycemic Control in KKAy Mice
April 30, 2011

Read More...
ETC-1002 Regulates Key Pathways of Lipid and Carbohydrate Metabolism in Primary Rat Hepatocytes through a Novel Acyl-CoA Synthetase-Dependent AMP-Activated Protein Kinase Mechanism
April 29, 2011

Read More...
ETC-1002 was Safe, Well-Tolerated and Reduced LDL-C in a Phase 1 Multiple-Dose Study of Subjects with Mild Dyslipidemia
April 29, 2011

Read More...
A Novel Small Molecule, ETC-1002, Lowers Proatherogenic Lipoproteins, Reduces Adiposity, and Improves Hepatic Steatosis in a Hyperlipidemic Hamster Model
April 29, 2011

Read More...
ETC-1002: A Novel Small Molecule Inhibitor of Lipogenesis Improves Plasma Lipid Profile and Inhibits Atherosclerosis Progression in LDLr-/- Mouse by Lipid-Dependent and Independent Mechanisms
April 29, 2011

Read More...